Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Point-of-care ARI-0001 versus Yescarta in relapsed/refractory DLBCL
NL-OMON54144Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ARI-0001 and axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL), sponsored by University Medical Center Groningen. Primary endpoint: Progression-free survival from IMP infusion. Started Oct 2022; status: recruiting.
02
Drugs
ARI-0001axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON54144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54144.